+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07481747

Study of Weekly Tirzepatide Injections for Adults With Obesity or Overweight and Related Health Issues Without Type 2 Diabetes

Led by Hudson Biotech · Updated on 2026-03-19

2539

Participants Needed

1

Research Sites

56 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of once-weekly subcutaneous tirzepatide at doses of 5 mg, 10 mg, or 15 mg compared to placebo in adults who are either obese or overweight with weight-related health conditions but do not have type 2 diabetes. This Phase 3 trial aims to assess weight changes primarily at 72 weeks. Participants with prediabetes at the start may continue treatment longer to study diabetes progression and extended weight outcomes. After screening, participants are randomly assigned to receive tirzepatide at one of three doses or a placebo via weekly subcutaneous injections using an autoinjector. All participants receive counseling on following a reduced-calorie diet and increasing physical activity. The main treatment phase lasts 72 weeks, with an optional extended treatment period up to 176 weeks for those with prediabetes to monitor long-term effects and diabetes progression. Safety is closely monitored throughout the study. Participants will have regular assessments including body weight measurements, cardiometabolic tests such as triglycerides, laboratory tests, and safety monitoring for side effects. Researchers will track the percentage of weight loss and other health changes at week 72, with ongoing evaluation during the longer treatment phase for some. The total participation time may extend beyond 176 weeks for eligible individuals, providing comprehensive data on tirzepatides impact combined with lifestyle changes.

CONDITIONS

Brief Title

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Research Team

S

Seni S Lu, Phd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here